SCHEMBL1969007

SCHEMBL1969007

CCc1cc2c(N3CCc4c([nH]n(C)c4=O)C3)nc(N3CCNC(=O)C3)nc2s1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 8/20 0.46
HTR6 P50406 1/20 0.42
KDM4E B2RXH2 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TMIGD3 P0DMS9 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
HTT P42858 1/20 0.36
NPC1 O15118 2/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
PRKCH P24723 1/20 0.33
PRKCE Q02156 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967292 0.89 P2RY12 (0.45) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1966413 0.87 P2RY12 (0.49) P2RY12HTR6SMN1; SMN2HTTMEN1
SCHEMBL1968096 0.84 HTR6 (0.46) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1965500 0.82 P2RY12 (0.49) P2RY12KDM4ERAB9ASMN1; SMN2TMIGD3
SCHEMBL1966828 0.81 P2RY12 (0.53) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1968122 0.80 P2RY12 (0.46) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1969825 0.79 P2RY12 (0.46) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1968516 0.79 P2RY12 (0.44) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1966322 0.79 P2RY12 (0.51) P2RY12HTR6KDM4ERAB9ASMN1; SMN2
SCHEMBL1967955 0.79 P2RY12 (0.43) P2RY12HTR6KDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 P2RY12 127/4885HTR6 3031/4885KDM4E 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.